Continue reading your story on the app
Continue reading your story in the magazine
How Tech Innovations Impact Cardiac Care
Cardiac care has seen a transformation over the years with technology playing an important role. Armed with Artificial intelligence (AI) and machine learning (ML), cardiac care providers, with the right technology, have received the right impetus to revolutionise treatment mechanisms. Let us delve into the new technologies which the industry is offering to mankind and decipher the way forward.
Mynvax Offers ‘Warm Vaccine' For COVID-19
Biotech startup Mynvax, incubated at the Indian Institute of Science (IISc) in Bengaluru, has developed heat-tolerant COVID-19 vaccine formulations.
“R&D outsourcing has become a ‘must have' than ‘good-to have' strategy”
Aragen Life Sciences (formerly GVK BIO), a leading contract research and development organisation headquartered in Hyderabad, is marking its transition to a new brand identity in its 20th year. Established in 2001, the company is poised for growth in the outsourced discovery, development, and manufacturing services sector across both large and small molecule platforms with new investments and collaborations. In conversation with BioSpectrum, Manni Kantipudi, Chief Executive Officer, Aragen Life Sciences, Hyderabad reveals more about the company’s recent rebranding and growth plans. Edited excerpts;
Premas Biotech to commercialise VLP vaccine tech against Delta variant
Gurugram-based Premas Biotech has signed a licensing deal with Oravax Medical for the development and commercialisation of its virus-like-particle COVID-19 vaccine technology.
SARS-CoV-2: A Biochemical Treatise on its Past, Present & Future
The SARS-CoV-2 pandemic is unprecedented but equally unprecedented is the contribution of scientists who have helped us in understanding the mechanisms by which it infects human beings and also, developing a variety of vaccines to protect the masses, in a year’s time, which can be called truly groundbreaking. This article gives an overview of the progress made by scientists around the world working round the clock in developing an understanding of the SARS-CoV-2 evolution and COVID-19 disease pathogenesis, and also makes an attempt to suggest the possible ways of coping with this pandemic if we have to co-exist with it forever!
Merck launches Pergoveris Pen for fertility treatment in India
Merck Specialties, the healthcare business of Merck in India, has launched Pergoveris Pen for advanced infertility treatment in India.
GUNG-HO PHARMA R&D INVESTMENTS SURPASS $3B
While the pharmaceutical industry helped combat COVID-19, from R&D actions on potential treatment strategies to balancing the medicines supply chain in the time of crisis, it struggled to maintain the natural market flow. As a result, many pharma companies had to abort some of their ongoing R&D investment plans. However for FY20-21, the average R&D expenses constituted 7.2 per cent of the total revenues of the pharma companies, with Lupin, Alembic Pharma and Dr. Reddy’s spending more than others. The cumulative R&D expenditure of the leading 10 pharma companies has been around Rs 10,627 crore ($1.43 billion) in the previous fiscal. This figure eventually reaches an approximate amount of Rs 22,500 crore ($3.03 billion) after considering the cumulative expenditure by other small and medium players of the India pharma industry.
Glenmark ties up with SaNOtize to commercialise COVID-19 nasal spray
Mumbai-based Glenmark Pharmaceuticals and Canadian biotech firm SaNOtize Research & Development Corporation
CEPI prioritises Rift Valley fever vax
Sep 01, Norway-based Coalition for Epidemic Preparedness Innovations (CEPI) has signed an implementing partner agreement with Integrum Scientific (US) as part of its ongoing efforts to combat Rift Valley fever (RVF)—one of its priority diseases with epidemic potential.
3D printing moulds healthcare innovations
Pharmaceuticals, bio-medicine, aviation, and automobiles industries have rapidly adopted 3D printing over the years, worldwide, to develop new solutions and prototypes. It is also helping many industries, healthcare, in particular, increase productivity. Despite all its advantages, 3D printing technology is currently posing a number of challenges in the market such as initial costs, limitation to the metals and plastics used for 3D printing, lack of policy standardisation, etc.
Working on many fronts to improve outlook
GNP to enhance its exiting brand franchise; focus on core therapies
Glenmark nasal spray cuts viral load by 94% in 24 hrs
LANCET STUDY ON COVID DRUG
Nasal spray market heats up as restrictions ease
Glenmark launches 1st commercially available spray, smaller firms to follow
ITC kicks off trials of nasal spray for Covid prevention
Diversified conglomerate ITC has started clinical trials of a nasal spray for Covid19 prevention.
Remogliflozin, vildagliptin, metformin FDC approved for Type 2 Diabetes in India
Mumbai-based drumaker Glenmark Pharmaceuticals received approval for its fixed dose combination (FDC) of remogliflozin (100 mg), vildagliptin (50 mg) and metformin (500/ 1000 mg from the Drug Controller General of India.
एचएनआई पर उल्टा पड़ा आईपीओ दांव
इस साल बाजार में बड़ी तादाद में आए आरंभिक सार्वजनिक निर्गमों (आईपीओ) में धनी (एचएनआई) निवेशकों ने जमकर मुनाफा कमाया। लेकिन इस महीने उनके ज्यादातर दांव कामयाब नहीं रहे।
Positive Q4 Results
The rising number of corona virus cases and earnings are the factors that may decide the market direction going forward. While the positive results have so far kept market momentum intact, the increasing spread of the second wave of the virus threatens to dislodge the positivity in the markets. Yogesh Supekar analyses the Q4 results while highlighting the hits and misses of the current earnings season while the DSIJ Research Team highlights the sector-wise earnings’ performance this season
अन्य दवाओं से सस्ती है फैबिफ्ल
ग्लेनमार्क ने औषधि नियामक को दिया जवाब, कहा फैबिफ्लू सस्ती एवं प्रभावी दवा है
ग्लेनमार्क ने 30 फीसदी घटाए फैविपिराविर के दाम
• कंपनी ने कीमत रखी थी 103 रुपये प्रति टैबलेट • 34 टैबलेट वाले पैक की कीमत थी 3,500 रुपये • अब 75 रुपये की पड़ेगी एक टैबलेट
घटेगी फैविपिराविर की कीमत
कई कंपनियां इसे बाजार में उतारने की तैयारी कर रही हैं, 40 प्रतिशत तक कम हो सकते हैं दाम